REFERENCES
- Candrilli SD, Davis KL, Iyer S. Impact of constipation on use patterns, health care resource utilization, and costs in cancer patients on therapy. J Pain Palliat Care Pharmacother. 2009;23:231–241.
- Simpson K, Leyendecker P, Hopp M, Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503–3512.
- Meissner W, Leyendecker P, Mueller-Lissner S, A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse induced constipation. Eur J Pain. 2009;13:56–64.
- Diego L, Atayee R, Helmons P, von Gunten CF. Methylnaltrexone: a novel approach for the management of induced constipation in patients with advanced illness. Expert Rev Gastroenterol Hepatol. 2009;3:473–485.
- Slatkin N, Thomas J, Lipman AG, Methylnaltrexone for treatment of induced constipation in advanced illness patients. J Support Oncol. 2009;7:39–46.
- Chamberlain BH, Cross K, Winston JL, Methylnaltrexone treatment of opiate-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009; In press.
- Saad R, Chey WD. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol. 2008;2:497–508.
- Lacy BE, Chey WD. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009;10:143–152.
- Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35–42.